ABCAM PLC Total Voting Rights (0700I)

TIDMABC

RNS Number : 0700I

ABCAM PLC

30 November 2022

 
 For immediate release   30 November 2022 
 

ABCAM PLC

("Abcam" or "Company")

Total Voting Rights - Voting Rights and Capital

In conformity with the Disclosure Rules and Transparency Rules, provision 5.6.1, the Company notifies the market of the following:

The Company's issued share capital consists of 229,271,907 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.

The above figure of 229,271,907 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Date of Notification: 30 November 2022

For further information please contact:

 
                                              + 44 (0) 1223 696 
Abcam                                                       000 
Marc Perkins, Company Secretary 
 
Numis - Nominated Adviser & Joint Corporate    + 44 (0) 20 7260 
 Broker                                                    1000 
Freddie Barnfield / Duncan Monteith 
 
  Morgan Stanley - Joint Corporate Broker       [phone] 
  Tom Perry / Luka Kezic                        8000 
 
  FTI Consulting                                [phone] 
  Ben Atwell / Julia Bradshaw                   1000 
 
 
 

Notes to Editors

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit corporate.abcam.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRWPGCAGUPPURU

(END) Dow Jones Newswires

November 30, 2022 03:55 ET (08:55 GMT)